What is Nutromics?
Nutromics is a pioneering health-tech enterprise dedicated to the advancement of Continuous Molecular Monitoring. The company is currently revolutionizing the diagnostic paradigm through its innovative lab-on-a-patch technology. This sophisticated hardware solution enables the real-time, continuous tracking of critical health indicators, providing clinicians and patients with longitudinal trend data that traditional, episodic lab testing cannot capture. By bridging the gap between intermittent diagnostics and actionable, dynamic health insights, Nutromics aims to significantly improve patient outcomes while simultaneously driving down systemic healthcare costs. Their market position is defined by a commitment to high-fidelity, non-invasive monitoring that empowers stakeholders to make informed, timely medical decisions.
How much funding has Nutromics raised?
Nutromics has raised a total of $19.7M across 2 funding rounds:
Unspecified
$5.7M
Other Financing Round
$14M
Unspecified (2021): $5.7M with participation from Artesian Capital Partners
Other Financing Round (2022): $14M led by Dexcom Ventures, VU Venture Partners, and Artesian Investments
Key Investors in Nutromics
Artesian Capital Partners
Artesian Capital Partners is an integrated firm that provides innovative financing solutions and specialized engineering support, often focusing on sustainable infrastructure and strategic growth capital.
VU Venture Partners
VU Venture Partners is a multi-stage global venture capital fund with a strong track record in the healthcare and frontier technology sectors, supporting companies through capital raising and strategic partnerships.
Dexcom Ventures
Dexcom Ventures is the corporate venture arm of a leading continuous glucose monitoring company, focusing on strategic investments in technologies that advance the future of medical diagnostics and patient care.
What's next for Nutromics?
With the recent influx of capital, Nutromics is well-positioned to transition its lab-on-a-patch technology from the research and development phase toward broader clinical validation and commercial deployment. The strategic focus will likely center on scaling manufacturing capabilities and navigating the complex regulatory pathways required for widespread adoption in clinical settings. Furthermore, the company is expected to leverage its investor network to forge key partnerships with healthcare providers, ensuring that its diagnostic tools are integrated into existing patient care workflows. As the firm matures, the emphasis will shift toward demonstrating long-term clinical efficacy and cost-effectiveness, which will be essential for securing future growth financing and achieving market leadership in the molecular monitoring space.
See full Nutromics company page
